Dr Reddy’s Laboratories has launched Ibandronate Sodium tablets (150 mg), a bioequivalent generic version of BONIVA tablets in the US market on June 29, 2012 following the approval by the United States Food & Drug Administration (USFDA) of Dr Reddy’s ANDA for Ibandronate sodium tablets.
The BONIVA brand and generic had US sales of approximately $486 million for the most recent twelve months ending March 2012 according to IMS Health.
Dr Reddy’s Ibandronate sodium tablets in 150 mg are available in cartons of three blister packs containing one tablet each (once monthly dosing).
EP News Bureau-Mumbai
